The association between human papillomavirus infection and female lung cancer
A population-based cohort study

Frank Cheau-Feng Lin (MD)a,b, Jing-Yang Huang (MSc)c, Stella Ching-Shao Tsai (MD)d,e, Oswald Ndi Nfor (DVM, MSc)f, Ming-Chih Chou (MD)g,h, Ming-Fang Wu (MD)i, Chun-Te Lee (MD)j,k, Cheng-Feng Jan (PhD)l, Yung-Po Liaw (PhD)m,n

Abstract
Lung cancer is the leading cause of cancer deaths among Taiwanese women. Human papillomavirus (HPV) has been detected in lung cancer tissues. The aim of this study was to investigate the association between HPV infection and lung cancer among the Taiwanese women. The analytical data were collected from the longitudinal health insurance database (LHID 2005 and 2010) of the National Health Insurance Research Database (NHIRD). The study participants were 30 years and older and included 24,162 individuals who were identified with HPV infection from 2001 to 2004 and 1,026,986 uninfected individuals. Lung cancer incidence among infected and uninfected individuals was compared using the univariate and multivariate regression models. Among the total participants, 24,162 individuals were diagnosed with HPV. After adjusting for age, gender, low income, residential area, and comorbidity, the risk of lung cancer was higher in women (hazard ratio [HR] 1.263, 95% CI 1.015–1.571), while all cancer risks were high in both men and women with corresponding hazard ratios (HR) of 1.161 (95% CI 1.083–1.245) and HR 1.240 (95% CI 1.154–1.331), respectively. This study showed a significant increase in lung cancer risk among Taiwanese women who were exposed to HPV infection.

Abbreviations: CI = confidence interval, EGFR = epidermal growth factor receptor, HPV = human papillomavirus, HR = hazard ratio, ICD-9-CM = International Classification of Diseases Clinical Modification, IRR = incidence rate ratio, LHD = longitudinal health insurance database, NHIRD = National Health Insurance Research Database.

Keywords: cohort, human papillomavirus, lung cancer, population-based

1. Introduction
Cancer has been reported as one of the leading causes of deaths among the Taiwanese since 1982 with approximately 20 to 30 deaths/100,000/year. The etiologies of cancer have been widely studied with genetic and environmental factors proven to play a major role. Viral infection is one of the most significant risk factors for cancer. Studies conducted in Taiwan have reported associations between hepatitis B virus infection and hepatocellular carcinoma. On the other hand, nasopharyngeal cancer has been linked with Epstein–Barr virus. Human papillomavirus has been shown to have a causal relationship with cervical cancer. However, immunization against the virus has been introduced within the public health sector.

Lung cancer is the leading cause of cancer death among Asian women particularly the Taiwanese. The most investigated and frequent cause of lung cancer is tobacco smoking. However, the incidence of female lung cancer has increased even without a concurrent increase in smoking among Asian populations. From 1981 to 2011, the female-to-male ratio for lung cancer increased rapidly from 1:3.3 to 1:2. Furthermore, a 3.3-fold increase in lung cancer death has been observed among Taiwanese women. The number of deaths due to cancer was 646 per 8.6 million in 1981 and 2782 per 11.5 million in 2010. Lung cancer incidence among female smokers in Taiwan was approximately 4% (2.3%–5.2%) in 1974. The cancer types were predominantly adenocarcinoma, often with epidermal growth factor receptor (EGFR) mutations, and which responded to treatment with tyrosine-kinase inhibitors.
among female nonsmokers may be regarded as a different disease entity and therefore, etiology other than smoking needs to be investigated. HPV has been reported in lung cancer tissues in Western and Eastern countries especially Asia. Types 16 and 18 have been the most common pathogenic species.\(^{13-16}\) HPV has also been found in the breast tissue, head, neck, esophageal, and anogenital regions.\(^{14,17-20}\)

A single-payer national health insurance was initiated in Taiwan since 1995 and has a coverage rate of about 99%. A nationwide population-based cohort study for cancer has been proven to be a reliable method to study the etiology of cancer.\(^{21-23}\) The aim of this study was to investigate the relationship between HPV and lung cancer among Taiwanese women.

2. Methods
The longitudinal health insurance databases (LHID 2005 and 2010) were used to collect data. Initially enrolled in this study were 25,653 individuals who were identified with HPV infection and 1,065,654 control individuals aged 30 years and older. Excluded were patients diagnosed with cancer from January 2001 to December 2004 and people aged 30 years and younger. Finally, 24,162 HPV-infected and 1,026,986 uninfected individuals were enrolled in the study (Fig. 1). HPV was identified using the International Classification of Diseases Clinical Modification (ICD-9-CM) codes 079.4, 078.1, 078.10–078.12, 078.19, 759.05, 795.09, 795.15, 795.19, 796.75 and 796.79.

The codes 140 to 208 were used for all cancer while 162 was for lung cancer. The crude incidence rate (per 1000 person-months) was calculated while the incidence rate ratio (IRR) with 95% confidence interval (CI) was estimated by Poisson regression. A 2-tailed \(t\) test was used to compare the mean difference between continuous variables while the \(\chi^2\) test was used for nominal variables. For the time to event analysis of the longitudinal follow-up, the event was defined as the date of cancer onset. Follow-up was censored when a patient quit the insurance or in a case of death. The Kaplan–Meier survival curves and multiple Cox regression model were used to calculate the relative risk of cancer. SAS software (version 9.3, SAS Institute Inc, Cary, NC) was used for analysis. A \(P<0.05\) was considered statistically significant. The study was approved by the Institutional Review Board of Chung Shan Medical University Hospital, Taichung, Taiwan (#CS13168).

3. Results
The prevalence of HPV infection was 2.30%. Table 1 shows the basic demographic characteristics of the study population. There was no significant age difference between the HPV-infected individuals (48.61±14.06 years) and their uninfected counterparts (48.73±13.65 years). The exposed or infected individuals had a significantly higher proportion of females (55.85%), less low income (0.45%), and higher proportions of specific comorbidities (including chronic obstructive pulmonary disease (COPD), ischemic heart disease, hypertension, diabetes mellitus, liver disease, and renal disease). Table 2 shows the incidence rates (per 1000 person-months) for all cancer and lung cancer and the IRR of the HPV-infected and uninfected individuals stratified by gender. The mean follow-up times of the infected and uninfected male participants were 67.72 and 67.88 months, respectively. The IRR for all types of cancer among the infected males was 1.423 (95% CI: 1.328–1.526), while that for lung cancer was 1.518 (95% CI: 1.278–1.802). Similarly, the IRR for all cancer among the infected females was 1.208 (95% CI: 1.125–1.297), whereas that for lung cancer was 1.181 (95% CI: 0.949–1.469). Figures 2 and 3 show the cumulative incidence rates for all types of cancer and lung cancer stratified by gender, while Tables 3 and

\[\text{Table 1.} \]

| HPV status | Study Population Characteristics |
|-----------|---------------------------------|
| HPV-infected | 24,162                          |
| Uninfected  | 1,026,986                      |

\[\text{Table 2.} \]

| HPV status | All Cancer Incidence Rate (per 1000 person-months) | Lung Cancer Incidence Rate (per 1000 person-months) | IRR (95% CI) |
|-----------|-----------------------------------------------|-----------------------------------------------|-------------|
| HPV-infected | 1.423 (1.328–1.526)                          | 1.518 (1.278–1.802)                          |             |
| Uninfected  | 1.208 (1.125–1.297)                          | 1.181 (0.949–1.469)                          |             |

\[\text{Figure 1.} \]

Flowchart of the study population.
In this study, a significant increase in lung cancer risk was found in females with HPV infection. Cigarette smoking, the modifiable risk factor for lung cancer, was not adjusted due to a dearth of information in the database. However, adjustments were made for COPD and smoking-induced diseases. From 2005 to 2010, all cancer incidence rates were higher in the exposed males and females. Similar results have been reported.\(^{14-20}\) COPD was the major risk factor for lung cancer in both males and females. Jian et al.\(^{24}\) have reported similar findings among lung cancer patients in Taiwan. Adjustments were also made for ischemic heart disease and hypertension associated with smoking\(^ {23}\) as well as diabetes mellitus which has also been associated with all cancer.\(^ {126,127}\) Surprisingly, liver disease was found to be an independent risk factor for lung cancer in this study. Hepatitis C infection has been implicated in the causation of lung cancer.\(^ {129,130}\) Liver disease especially chronic viral hepatitis has been associated with hepatocellular carcinoma. Hepatocellular carcinoma is capable of metastasizing to the lung through the inferior vena cava. More studies are required to clarify such mechanisms.

The leading cause of lung cancer is cigarette smoking.\(^ {8,30,31}\) Other suspected risk factors include passive smoking and cooking oil fumes, especially among Chinese women.\(^ {31-33}\) In China, indoor air pollution has been associated with lung cancer.\(^ {34}\) Air pollution has also been recognized recently as a carcinogen, especially for adenocarcinoma in females though the concept has long been suggested.\(^ {35,36}\) The incidence of cancer has been attributed to the presence of heavy metals such as arsenic in soil and water.\(^ {37,38}\) These risk factors would not be identified by analysis of the ICD-9-CM designations used in this study.

There is an extensive literature regarding HPV association with laryngeal and cervical cancer but HPV is also associated with other cancers, including lung cancer. Women with anogenital malignancy and HPV have been reported with a higher relative risk of lung cancer.\(^ {39,40}\) HPV has been detected in lung cancer tissue since 1979.\(^ {4,41,42}\) It was first detected in squamous cell carcinoma. The morphological characteristic was similar to that of condyloma and cervical cancer. In a meta-analysis, 22.4% of lung cancer tissues particularly adenocarcinoma and squamous carcinoma. The morphological characteristic was similar to that of condyloma and cervical cancer. In a meta-analysis, 22.4% of lung cancer tissues particularly adenocarcinoma and squamous cell carcinoma had HPV predominantly types 16 and 18.\(^ {43}\) Other pathological types of HPV have also been investigated. In Taiwan, HPV 16/18 DNA has been detected in 54.6% of lung cancer tissues whereas the surrounding normal lung tissues were spared. The odds ratio for HPV 16/18 infection of lung cancer

### Table 1
Demographic characteristics of HPV-exposed and nonexposed individuals in 2005.

|                     | Exposed (n=24,162) | Nonexposed (n=1,026,886) | P value |
|---------------------|--------------------|--------------------------|---------|
| Age in 2005, Mean±SD| 48.61±14.06        | 48.73±13.65              | 0.1714  |
| Sex                 |                    |                          |         |
| Females             | 13,495 (55.85)     | 509,194 (49.58)          |         |
| Males               | 10,667 (44.15)     | 517,792 (50.42)          |         |
| Low-income          |                    |                          |         |
| No                  | 24,054 (99.55)     | 1,020,149 (99.33)        | <0.0001 |
| Yes                 | 108 (0.45)         | 6837 (0.67)              |         |
| Residential area    |                    |                          |         |
| Taipei area         | 9661 (39.98)       | 373,247 (36.34)          |         |
| Northern            | 2865 (11.86)       | 139,858 (13.62)          |         |
| Central             | 4730 (19.58)       | 182,801 (17.80)          |         |
| Southern            | 2697 (11.16)       | 147,881 (14.40)          |         |
| Kaohsiung area      | 3727 (15.43)       | 156,625 (15.49)          |         |
| Eastern             | 482 (1.90)         | 24,574 (2.38)            |         |
| Comorbidity         |                    |                          |         |
| COPD                | 2881 (11.92)       | 93,041 (90.67)           | <0.0001 |
| Ischemic heart disease | 3242 (13.42)   | 103,075 (10.04)          | <0.0001 |
| Hypertension        | 5202 (21.53)       | 194,123 (18.90)          | <0.0001 |
| Diabetes mellitus   | 2956 (12.23)       | 110,901 (10.80)          | <0.0001 |
| Ischemic stroke     | 726 (3.00)         | 29,480 (2.87)            | 0.2172  |
| Liver disease       | 5342 (22.11)       | 159,896 (15.57)          | <0.0001 |
| Renal disease       | 1621 (6.71)        | 52,615 (5.12)            | <0.0001 |

HPV, human papillomavirus; SD, standard deviation.

### Table 2
Cancer incidence among the infected and uninfected participants from 2005 to 2010.

|                     | Infected participants | Uninfected participants | Incidence rate ratio (95 % CI) | P value |
|---------------------|----------------------|-------------------------|-------------------------------|---------|
| Males               |                      |                         |                               |         |
| Follow-up months, mean±SD | 67.72±11.93         | 67.88±11.74             |                               |         |
| Event number (crude incidence rate/1000 person-months) | | | | |
| All cancer          | 817 (1.13)           | 27,463 (0.79)           | 1.423 (1.328–1.526)           | <0.0001 |
| Lung cancer         | 134 (0.18)           | 4184 (0.12)             | 1.518 (1.278–1.802)           | <0.0001 |
| Females             |                      |                         |                               |         |
| Follow-up months, mean±SD | 68.69±10.12         | 68.35±10.96             |                               |         |
| Event number (crude incidence rate/1000 person-months) | | | | |
| All cancer          | 782 (0.84)           | 24,730 (0.70)           | 1.208 (1.125–1.297)           | <0.0001 |
| Lung cancer         | 83 (0.09)            | 2683 (0.08)             | 1.181 (0.949–1.469)           | 0.1353  |
tissue in female nonsmokers was about 4 and 11 times more than that of the male smokers and was about 2-fold higher in adenocarcinoma than squamous cell carcinoma.\textsuperscript{[44]} Transmission of HPV to the lungs is another issue of interest. HPV DNA and mRNA have been detected in the peripheral blood of patients with cervical cancer.\textsuperscript{[45,46]} The implication was that the HPV went through the bloodstream to the heart, and then to the lung. Lungs are reticuloendothelial system rich organs which may capture the virus. It is also possible that the HPV DNA/mRNA detected in the blood may have originated from metastasized cancer cells. However, this could not be clarified in this study because the data could not be separated by the site of HPV infection. In another study, HPV 16/18 DNA was detected in 47.7% of the blood from patients with lung cancer. The odds ratios for lung cancer in patients with HPV 16/18 ranged from 6 to 10.\textsuperscript{[47]} The virus is able to spread from superficial sites of the body via blood to the periphery of the lungs where they are trapped. The peripheral sites of the lung are prone to adenocarcinoma. This might explain why HPV-infected female nonsmokers were more likely to have adenocarcinoma.\textsuperscript{[48]} HPV has also induced adenocarcinoma in cervix.\textsuperscript{[49]} Other transmission routes include the foregut through the airway to the lung. Transmission of HPV from the oral cavity to the lungs has also been reported.\textsuperscript{[50]} The HPV E6 oncoprotein reduces the tumor suppressor p53 through the E6-associated protein-mediated ubiquitin pathway and results in tumorigenesis in cervical cancer.\textsuperscript{[51,52]} This mechanism was also observed in lung cancer.\textsuperscript{[53]} The HPV E7 oncoprotein promotes degradation of tumor suppressors Rb family via the ubiquitin-proteasomal-mediated pathway and interferes with the relationship of Rb family protein and E2F transcription family, hence inducing tumorigenesis. The damages of retinoblastoma-Cyclin D1-p16 cell cycle pathway are important in the carcinogenesis of lung cancer.\textsuperscript{[54]}

This study did not particularly focus on adenocarcinoma. The study limitations include the following: first, the NHIRD does not contain information about lifestyle, smoking status, and smog, hence adjustments could not be made for such variables. Second, the database does not provide detailed ICD-9-CM codes for oral, pharynx, or laryngeal papilloma. This makes it difficult to
compare the incidence of oral and laryngeal papilloma with lung cancer based on the ICD-9-CM. Third, although HPV types 16, 18, and 31 are risk factors for lung cancer, the pathologic types could not be determined using the ICD-9 CM code. Lastly, there is a possibility of a coding error in the administrative datasets. The strength of this study lies in the use of a large database. In addition, there was a complete follow-up, potential bias due to small sample sizes and limited demographics were reduced. In conclusion, this study suggests that HPV infection is an important risk factor for lung cancer among women in Taiwan. COPD was the most significant independent risk factor lung cancer. Vaccination against HPV can theoretically prevent lung cancer. However, future studies ought to focus on the effectiveness of HPV vaccine in preventing lung cancer.

### Table 3
Cox regression analysis of HPV and lung cancer in males.

|                | All cancer | P value | Lung cancer | P value |
|----------------|------------|---------|-------------|---------|
| HPV infection  |            |         |             |         |
| (ref: general population) | 1.161 (1.083–1.245) | <0.0001 | 1.169 (1.084–1.390) | 0.0754 |
| Age in 2005 (per year) | 1.052 (1.051–1.053) | <0.0001 | 1.072 (1.070–1.075) | <0.0001 |
| Low-income | |         |             |         |
| No | | 1 | | 1 |
| Yes | 1.006 (0.888–1.140) | 0.9238 | 1.148 (0.866–1.522) | 0.3733 |
| Residential area | |         |             |         |
| Taipei area | | 1 | | 1 |
| Northern | 0.941 (0.907–0.978) | 0.0018 | 0.847 (0.765–0.938) | 0.0015 |
| Central | 0.954 (0.922–0.987) | 0.0068 | 1.158 (1.063–1.260) | 0.0007 |
| Southern | 1.054 (1.018–1.092) | 0.0028 | 1.115 (1.019–1.220) | 0.0182 |
| Kaohsiung area | 0.938 (0.905–0.972) | 0.0044 | 1.039 (0.949–1.138) | 0.4061 |
| Eastern | 0.918 (0.851–0.990) | 0.0259 | 1.077 (0.902–1.287) | 0.4115 |
| Comorbidity (ref: without) | |         |             |         |
| COPD | 1.157 (1.121–1.196) | <0.0001 | 1.615 (1.501–1.737) | <0.0001 |
| Ischemic heart disease | 1.086 (1.032–1.142) | 0.0011 | 1.032 (0.954–1.115) | 0.4983 |
| Hypertension | 1.072 (1.041–1.103) | <0.0001 | 0.970 (0.903–1.041) | 0.3988 |
| Diabetes mellitus | 1.152 (1.116–1.190) | <0.0001 | 1.153 (1.067–1.260) | 0.0003 |
| Ischemic stroke | 0.976 (0.930–1.024) | 0.3160 | 1.014 (0.909–1.132) | 0.8013 |
| Liver disease | 1.552 (1.511–1.595) | <0.0001 | 1.039 (1.019–1.220) | 0.0182 |
| Renal disease | 1.150 (1.105–1.198) | <0.0001 | 0.972 (0.877–1.078) | 0.5944 |

### Table 4
Cox regression analysis of HPV and lung cancer in females.

|                | All cancer | P value | Lung cancer | P value |
|----------------|------------|---------|-------------|---------|
| HPV infection  |            |         |             |         |
| (ref: general population) | 1.240 (1.154–1.331) | <0.0001 | 1.263 (1.015–1.571) | 0.0367 |
| Age in 2005 (per year) | 1.034 (1.033–1.035) | <0.0001 | 1.063 (1.060–1.066) | <0.0001 |
| Low income | |         |             |         |
| No | | 1 | | 1 |
| Yes | 1.260 (1.096–1.450) | 0.0012 | 1.227 (1.086–1.867) | 0.3399 |
| Residential area | |         |             |         |
| Taipei area | | 1 | | 1 |
| Northern | 0.923 (0.887–0.961) | <0.0001 | 0.879 (0.773–1.000) | 0.0497 |
| Central | 0.871 (0.840–0.903) | <0.0001 | 1.084 (0.975–1.210) | 0.1352 |
| Southern | 0.991 (0.965–1.028) | 0.0621 | 1.055 (0.982–1.211) | 0.0930 |
| Kaohsiung area | 0.852 (0.820–0.885) | <0.0001 | 0.945 (0.841–1.061) | 0.3384 |
| Eastern | 0.798 (0.732–0.871) | <0.0001 | 0.780 (0.660–1.030) | 0.0815 |
| Comorbidity (ref: without) | |         |             |         |
| COPD | 1.173 (1.131–1.216) | <0.0001 | 1.461 (1.326–1.609) | <0.0001 |
| Ischemic heart disease | 1.104 (1.065–1.144) | <0.0001 | 1.096 (0.996–1.207) | 0.0617 |
| Hypertension | 1.014 (0.982–1.048) | 0.3907 | 1.012 (0.925–1.108) | 0.7930 |
| Diabetes mellitus | 1.092 (1.005–1.133) | <0.0001 | 1.022 (0.927–1.127) | 0.6564 |
| Ischemic stroke | 0.996 (0.939–1.057) | 0.9034 | 0.799 (0.678–0.942) | 0.0076 |
| Liver disease | 1.450 (1.407–1.496) | <0.0001 | 1.258 (1.199–1.328) | <0.0001 |
| Renal disease | 1.215 (1.161–1.270) | <0.0001 | 1.116 (0.979–1.272) | 0.1003 |
References

[1] 2010 Statistics of Causes of Death, 2011; Available at: http://www.doh.gov.tw/afds/doc/2010-statistics%20of%20cause%20of%20death.pdf. Accessed April 26, 2012.

[2] Spano JP, Russon P, Atlan D, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003;39:212–35.

[3] Bosch F, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–63.

[4] Anorlu R. What is the significance of the HPV epidemic? Can J Urol 2008;15:3860–5.

[5] zur Hausen H. Human papillomavirus & cervical cancer. Indian J Med Res 2011;133:1297.

[6] Finn OJ, Edwards RP. Human papillomavirus vaccine for cancer prevention. N Engl J Med 2009;361:1899–901.

[7] Jamrozik K, Musk AW. Respiratory health issues in the Asia-Pacific region: an overview. Respiriology 2011;16:3–12.

[8] Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never-smokers—a review. Eur J Cancer 2012;48:1299–311.

[9] Wang BY, Huang JY, Cheng CY, et al. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol 2013;8:1128–35.

[10] Ger LP, Liu SH, Shen CY, et al. Risk factors of lung cancer. J Formosan Med Assoc 1992;91:S222–31.

[11] Adult Smoking Behavior Survey (ASBS). 2015; Available at http://www.hpa.gov.uk/English/ClassShow.asp?cNo=20150200040.

[12] Gao AF. EGFR mutations in lung cancer: different frequencies for different folks. J Thorac Oncol 2014;9:139–40.

[13] Hayatsu T, Iwamasa T, Kamada Y, et al. Human papillomavirus DNA in squamous cell carcinoma of the lung. J Clin Pathol 1996;49:810–7.

[14] Giuliani L, Favalli C, Siryjan K, Ciotti M. Human papillomavirus infections in lung cancer. Detection of E6 and E7 transcripts and review of the literature. Anticancer Res 2007;27:2697–94.

[15] Kishinoto I, Dosaka-Akita H, Shindoh M, et al. Human papillomavirus type 18 DNA and E6-E7 mRNA are detected in squamous cell carcinoma and adenocarcinoma of the lung. Br J Cancer 1995;71:344–9.

[16] Zafei E, Ergun MA, Alver G, et al. Detection and typing of human papillomavirus in non-small cell lung cancer. Respiration 2004;71:88–90.

[17] Habeck M. New data confirm that HPV can cause oropharyngeal cancer. Mol Med Today 2000;6:e297.

[18] Vaiphei K, Kochhar R, Bhardawaj S, et al. High prevalence of human papillomavirus in esophageal squamous cell carcinoma: a study in paired samples. Dise Esophagus 2013;26:282–7.

[19] Loning T, Riviere A, Kocher L, et al. Penile/anal condylomas and squamous cell cancer. A HPV DNA hybridization study. Virchows Arch 1999;438:491–8.

[20] zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9–13.

[21] Hung MC, Hwang JJ. Cancer risk from medical radiation procedures for coronary artery disease: a nationwide population-based cohort study. Asian Pacific J Cancer Prev 2013;14:2781.

[22] Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014;12:665–73.

[23] Liang JA, Sun LM, Su KP, et al. A nationwide population-based cohort study: will anxiety disorders increase subsequent cancer risk? PLoS One 2012;7:e36370.

[24] Jan ZH, Lung CC, Huang JY, et al. The coexistence of common pulmonary diseases on the histologic type of lung cancer in both genders in Taiwan: a STROBE-compliant article. Medicine (Baltimore) 2014;93:e127.

[25] Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011;378:1297–305.

[26] Zhang ZJ, Li Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol 2014;180:11–4.

[27] Tsai MJ, Yang CJ, King YT, et al. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner. Lung Cancer 2014;86:137–43.

[28] Prasad R, Husain N, Karmakar S, Verma S. Lung cancer and Hepatitis C virus. South Asian J Cancer 2013;2:86.

[29] Swart A, Burns L, Mao L, et al. The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. BMJ Open 2012;2:e001755.

[30] Ko YC, Lee CH, Chen MJ, et al. Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997;26:24–31.

[31] Rachtan J. Smoking, passive smoking and lung cancer cell types among non-smokers. J Thorac Oncol 2013;8:111–7.

[32] Mu L, Liu L, Niu R, et al. Indoor air pollution and risk of lung cancer among Chinese female non-smokers. Cancer Causes Control 2013;24:439–50.

[33] Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013;14:813–22.

[34] Liaw YP, Ting TF, Ho KK, Yang CF. Cell type specificity of lung cancer associated with air pollution. Sci Total Environ 2008;393:23–7.

[35] Mu L, Liu L, Niu R, et al. Indoor air pollution and risk of lung cancer among Chinese female non-smokers. Cancer Causes Control 2013;24:439–50.

[36] Rabkin CS, Biggar RJ, Curtiss RE. Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. Am J Epidemiol 1992;136:34–8.

[37] Frisch M, Melbye M. Risk of lung cancer in pre- and post-menopausal women with ano-genital malignancies. Int J Cancer 1995;62:508–11.

[38] Siryjan K. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. Respiration 1979;38:299–304.

[39] Cheng YW, Chiou HL, Shyu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799–803.

[40] Cheng YW, Chiou HL, Shyu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799–803.

[41] Tseng CJ, Pao CC, Lin JD, et al. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. J Clin Oncol 1999;17: 1391–6.

[42] Liu VW, Tsang P, Yip A, et al. Low incidence of HPV DNA in sera of pretreatment cervical cancer patients. Gynecol Oncol 2001;82:269–72.

[43] Chios HL, Wu MF, Liaw YC, et al. The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. Cancer 2003;97:1558–63.

[44] Yoshida J, Nagai K, Yokose T, et al. Primary peripheral lung carcinoma smaller than 1cm in diameter. Chest 1998;114:710–2.

[45] Tenti P, Pavanello S, Padovan L, et al. Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. Am J Pathol 1998;152:1015–63.

[46] Wilde E, Daggas MA, Field SK. Bronchogenic squamous cell carcinoma complicating localized recurrent respiratory papillomatosis. Chest 1994;105:1887.

[47] Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999;18:7690.

[48] Buitrago-Perez A, Garayuget G, Vazquez-Carballo A, et al. Molecular signature of HPV-induced carcinogenesis: pRb, p53 and gene expression profiling. Curr Genomics 2009;10:26–34.

[49] Cheng YW, Wu MF, Wang J, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007;67:10866–93.

[50] Wikman H, Kettunen E. Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Expert Rev Anticancer Ther 2006;6:515–30.